Adial Pharmaceuticals Inc
Last updated September 27, 2026
Organization details
- Legal name
- Adial Pharmaceuticals Inc
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ADIL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001513525
Board of directors
-
Bankole A. Johnson · DirectorSince 2023
-
Cary J. Claiborne · Director · Chief Executive OfficerSince 2023
-
J. Kermit Anderson · DirectorSince 2023
-
James W. Newman Jr. · DirectorSince 2023
-
Kevin Schuyler · DirectorSince 2023
-
Robertson H. Gilliland · DirectorSince 2023
-
Tony Goodman · Director · Chief Operating OfficerSince 2023
-
William B. Stilley III · DirectorSince 2023
Chief executives
Cary J. Claiborne
· Chief Executive Officer
Dates unknown
Board connections
2 of this board's directors also sit on 2 other boards.
- via William B. Stilley III
- via Kevin Schuyler
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 29, 2023 | Kevin Schuyler Director | Open-market purchase | +700 | $2.74 | $1,918 |
| May 23, 2023 | Truluck Joseph Officer (Chief Financial Officer) | Grant or award | +157,500 | — | — |
| May 23, 2023 | William B. Stilley III Director | Grant or award | +240,800 | — | — |
| May 23, 2023 | Cary J. Claiborne Director, Officer (Chief Executive Officer) | Grant or award | +420,000 | — | — |
| Dec 30, 2022 | William B. Stilley III Director | Sold back to the company | −166,667 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.